Top 10 Amantadine (Symmetrel) Generic Manufacturers in India
The Indian pharmaceutical industry is a global leader in the production of generic drugs, with a market size projected to reach USD 55 billion by 2025. India accounts for approximately 20% of the global generic drug market, exporting to over 200 countries. Amantadine, marketed under the brand name Symmetrel, is widely used in the treatment of Parkinson’s disease and certain types of influenza. The demand for its generic forms is growing, driven by rising healthcare costs and the increasing prevalence of viral infections and neurodegenerative diseases. Below is a comprehensive list of the top 10 manufacturers of Amantadine in India.
1. Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical, one of the largest pharmaceutical companies in India, holds a significant market share in the generic segment. With a production capacity of over 1,200 formulations, the company has a robust presence in both domestic and international markets. As of 2022, Sun Pharma reported revenues of approximately USD 4.5 billion, largely contributing to its strong position in the amantadine market.
2. Cipla Limited
Cipla is known for its extensive portfolio of generic drugs, including amantadine. The company has a production capacity of over 60 million units annually and reported a revenue of USD 3.4 billion in 2022. Cipla’s commitment to affordable healthcare has made it a key player in the generic amantadine market.
3. Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is a major player in the Indian pharmaceutical market, with a diverse range of over 190 generic drugs. The company’s production capacity stands at approximately 40 million units per year. In 2022, Dr. Reddy’s registered revenues of USD 2.4 billion, reflecting its strong foothold in the amantadine segment.
4. Aurobindo Pharma
Aurobindo Pharma specializes in generic formulations and API (Active Pharmaceutical Ingredients), producing over 300 generic drugs. With a production capacity exceeding 1,000 tons per year, the company reported a revenue of around USD 2.6 billion in 2022. Aurobindo’s strategic expansion into the global market has reinforced its position in the amantadine sector.
5. Zydus Cadila
Zydus Cadila, a prominent player in the Indian pharmaceutical industry, offers a broad range of generics, including amantadine. The company has production facilities capable of manufacturing over 1 billion doses annually. In 2022, Zydus Cadila reported revenues of approximately USD 2 billion, further strengthening its market presence.
6. Glenmark Pharmaceuticals
Glenmark Pharmaceuticals focuses on developing generics and specialty medications. The company produces over 200 generic drugs, and its production capacity is estimated at 700 million units per year. Glenmark reported revenues of USD 1.5 billion in 2022, showcasing its success in the amantadine market.
7. Torrent Pharmaceuticals
With a strong emphasis on research and development, Torrent Pharmaceuticals manufactures a wide range of generic medications, including amantadine. The company has a production capacity of over 500 million units and reported revenues of USD 1.4 billion in 2022, reflecting its commitment to quality and affordability.
8. Alkem Laboratories
Alkem Laboratories is recognized for its extensive portfolio of generic drugs. The company produces over 700 formulations and has a production capacity of approximately 600 million units annually. In 2022, Alkem reported revenues of USD 1.1 billion, emphasizing its growing role in the amantadine market.
9. Mylan (now part of Viatris)
Mylan, now a part of Viatris, has a significant presence in the Indian generic market, producing various medications, including amantadine. The company has a production capacity of over 2 billion units annually. Mylan reported revenues of approximately USD 11.5 billion globally in 2022, indicating its strong global reach and influence.
10. Hetero Drugs Limited
Hetero Drugs Limited specializes in producing generic pharmaceuticals, including a range of antiviral medications. The company has production facilities with a capacity of over 1 billion units. In 2022, Hetero reported revenues of approximately USD 1 billion, highlighting its key role in the amantadine market.
Insights and Trends
The Indian pharmaceutical market continues to witness robust growth, with generic drug manufacturing expected to reach USD 65 billion by 2025. The increasing prevalence of chronic diseases and a growing geriatric population are propelling the demand for generics, including amantadine. Furthermore, the COVID-19 pandemic emphasized the need for affordable antiviral medications, pushing companies to invest in R&D and expand their production capabilities. As of 2023, India is expected to contribute to more than 20% of global generic drug exports, reinforcing its position as a leader in the pharmaceutical sector.
Related Analysis: View Previous Industry Report
